Commentary on the Challenges of Establishing Gene Medicines as a New Class of Therapeutics

Abstract

The potential value of the field of gene medicines is currently poorly understood by the media, public and financial community and those of the scientific and medical communities not directly involved in the field. This is unfortunate but based on historic precedent with other new classes of therapeutics would actually be expected at this stage of the field's development. This problem can only be remedied through clear demonstration of patient benefit and consistent communication of this benefit.